Noticias y vídeos - CRYOPORT INC. - Página 2

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX PR Newswire NEW YORK, July 18, 2023 NEW YORK , July 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Cryoport and certain of its officers and/or...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or “the Company”) (NYSE: CYRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cryoport announced its financial results for the second quarter on July 12, 2023. The Company disclosed...

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cryoport announced its financial results for the second quarter on...

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX ) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Cryoport investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit...

Law Offices of Howard G. Smith announces an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX ) investors concerning the Company’s possible violations of federal securities laws. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, at the midpoint,...

The Law Offices of Frank R. Cruz announces an investigation of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX ) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of...

Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations PR Newswire NASHVILLE, Tenn., July 12, 2023 Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients Second quarter revenue expected in the range of $56.5 - $57.5 million Full year 2023 revenue now expected in the range of $233 - $243 million Long-term outlook robust with...

IVFAustralia Selects Cryoport as Exclusive Supply Chain Solutions Provider PR Newswire SYDNEY and NASHVILLE, Tenn., June 29, 2023 SYDNEY and NASHVILLE, Tenn. , June 29, 2023 /PRNewswire/ -- IVFAustralia , an Australian-based provider of full-service fertility care, IVF and related services as part of the Virtus Health network, and Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions supporting the life...

Cryoport Reports First Quarter 2023 Results PR Newswire NASHVILLE, Tenn., May 4, 2023 Record revenue of $63 million , representing 20% growth year-over-year Growth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reproductive Medicine revenue up 13% year-over-year Commercial Cell and Gene Therapy revenue up 28% year-over-year, now supporting 82 Phase 3 clinical trials Strong balance sheet with $523 million in cash and short-term investments NASHVILLE,...

Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023 PR Newswire NASHVILLE, Tenn., April 27, 2023 NASHVILLE, Tenn. , April 27, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that the Company will report financial results for the first quarter ended March 31, 2023 on...

Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S. PR Newswire NASHVILLE, Tenn., April 25, 2023 NASHVILLE, Tenn. , April 25, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that it has signed a new three-year...

Cryoport Announces Multi-Year Agreement with Inception Fertility PR Newswire NASHVILLE, Tenn., March 28, 2023 Cryoport to Support The Prelude Network ® and MyEggBank ® 's Reproductive Material Shipments with its end-to-end supply chain solutions NASHVILLE, Tenn. , March 28, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply...

Cryoport Confirms No Financial Exposure to Silicon Valley Bank PR Newswire NASHVILLE, Tenn., March 13, 2023 NASHVILLE, Tenn. , March 13, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, today confirms that the Company does not have any exposure or business relationship with...

Cryoport Reports Fourth Quarter and Full Year 2022 Results PR Newswire NASHVILLE, Tenn., Feb. 23, 2023 2022 revenue reached a record $237 million , commercial revenue up 27% year-over-year Now supporting a record 654 global clinical trials and 10 commercial therapies Entering 2023 with $523 million in cash and short-term investments Revenue guidance for the full year 2023 of $270 - $290 million , up 18% year-over-year at the mid-point NASHVILLE, Tenn. , Feb. 23, 2023 /PRNewswire/ -- Cryoport,...

Cryoport to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 PR Newswire NASHVILLE, Tenn., Feb. 15, 2023 NASHVILLE, Tenn. , Feb. 15, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced that the Company will report financial results for the...

Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies PR Newswire NASHVILLE, Tenn., Jan. 18, 2023 Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on...

Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference PR Newswire NASHVILLE, Tenn., Dec. 20, 2022 NASHVILLE, Tenn. , Dec. 20, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton , the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January...

Cryoport Reports Results for the Third Quarter 2022 PR Newswire NASHVILLE, Tenn., Nov. 3, 2022 Third quarter revenue of $60.5 million ; nine months 2022 revenue reaches $176.9 million ; Cryoport Systems' revenue up 25% year-over-year $530 million in cash and short-term investments Supporting a record 643 global clinical trials; 61 net new trials added (year-over-year) Entered strategic relationship with Takeda's BioLife Plasma Services for apheresis collection and leukopak production Record...

Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022 PR Newswire NASHVILLE, Tenn., Oct. 27, 2022 NASHVILLE, Tenn. , Oct. 27, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended September 30, 2022 (third quarter 2022) on Thursday, November 3, 2022 after...

Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services PR Newswire NASHVILLE, Tenn., Sept. 8, 2022 Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services in United States and Europe over time NASHVILLE, Tenn. , Sept. 8, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply...